POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation

BRAF inhibitors (BRAFi) have shown remarkable clinical efficacy in the treatment of melanoma with BRAF mutation. Nevertheless, most patients end up with the development of BRAFi resistance, which strongly limits the clinical application of these agents. POU4F1 is a stem cell-associated transcription...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cell Death Dis
Autori principali: Liu, Lin, Yue, Qiao, Ma, Jingjing, Liu, Yu, Zhao, Tao, Guo, Weinan, Zhu, Guannan, Guo, Sen, Wang, Shiyu, Gao, Tianwen, Li, Chunying, Shi, Qiong
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7293281/
https://ncbi.nlm.nih.gov/pubmed/32532957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-020-2662-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi